Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM 2B
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) ranks among the most lethal cancers, with current therapies offering only palliation. Inter‐ and intrapatient heterogeneity is a hallmark of GBM, with epigenetically distinct cancer stem‐like cells (CSC s) at the apex. Targeting GSC s remains a challenging task because of their unique biology, resemblance to normal neural stem/progenitor cells, and resistance to standard cytotoxic therapy. Here, we find that the chromatin regulator, JmjC domain histone H3K36me2/me1 demethylase KDM 2B, is highly expressed in glioblastoma surgical specimens compared to normal brain. Targeting KDM 2B function genetically or pharmacologically impaired the survival of patient‐derived primary glioblastoma cells through the induction of DNA damage and apoptosis, sensitizing them to chemotherapy. KDM 2B loss decreased the GSC pool, which was potentiated by coadministration of chemotherapy. Collectively, our results demonstrate KDM 2B is crucial for glioblastoma maintenance, with inhibition causing loss of GSC survival, genomic stability, and chemoresistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“To assess the efficacy of combinational treatments on cell viability (MTT), the free available COMPUSYN software for calculation of a combination index (CI) was used (Chou, 2010).”
MethodDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“The genome is under constant assault by endogenous factors—such as reactive oxygen species, metabolic intermediates, replication errors; and exogenous factors, such as ultraviolet (UV) radiation and environmental toxins (Bartek et al., 2007; Bartkova et al., 2005).”
BackgroundChromatin Remodeling at DNA Double-Strand Breaks
Price, B. D., & D’Andrea, A. D. (2013) · Cell · doi:10.1016/j.cell.2013.02.011 · Cited by 588
DNA damage signalling guards against activated oncogenes and tumour progression
Bartek, J., Bartkova, J., & Lukas, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210881 · Cited by 521
Hayami, S., Kelly, J. D., Cho, H., Yoshimatsu, M., Unoki, M., Tsunoda, T., Field, H. I., Neal, D. E., Yamaue, H., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25349 · Cited by 489 · cited 1×
“Several histone demethylases, including LSD1, KDM5A, and KDM5B, are upregulated in malignant gliomas, sustaining cell growth, and resistance to chemotherapy (Amente et al., 2015; Banelli et al., 2015; Black et al., 2013; Dai et al., 2014; Hayami et al., 2011; Tzatsos et al., 2013).”
BackgroundPharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
Hashizume, R., Andor, N., Ihara, Y., Lerner, R., Gan, H., Chen, X., Fang, D., Huang, X., Tom, M. W., Ngo, V., et al. (2014) · Nature Medicine · doi:10.1038/nm.3716 · Cited by 476 · cited 5×
“Pathophysiologically, there are strong links between the expression of certain histone demethylases, chromatin remodeling, and the initiation as well as maintenance of cancer (Hashizume et al., 2014; Maes et al., 2015; Pedersen and Helin, 2010; Rotili and Mai, 2011).”
BackgroundInfluentialLocal generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation
Jiang, Y., Qian, X., Shen, J., Wang, Y., Li, X., Liu, R., Xia, Y., Chen, Q., Peng, G., Lin, S.-Y., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3209 · Cited by 208
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Miller, T. E., Liau, B. B., Wallace, L. C., Morton, A. R., Xie, Q., Dixit, D., Factor, D. C., Kim, L. J. Y., Morrow, J. J., Wu, Q., et al. (2017) · Nature · doi:10.1038/nature23000 · Cited by 200
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135 · cited 3×
“Open chromatin augments sensitivity to DNA damage, and the KDM2 family regulates DNA damage repair and correlates with treatment resistance in several cancer types (Banelli et al., 2015; Ramadoss et al., 2017).”
BackgroundInhibition of histone deacetylases sensitizes glioblastoma cells to lomustine
Staberg, M., Michaelsen, S. R., Rasmussen, R. D., Villingshøj, M., Poulsen, H. S., & Hamerlik, P. (2017) · Cellular Oncology · doi:10.1007/s13402-016-0301-9 · Cited by 62 · cited 1×
“The MTT assay (Sigma M-5655) was employed (Figs 1F, 4, 5A and 6) as previously described (Staberg et al., 2017).”
MethodSelf-citation
Cited by
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
“Besides KDM5A, other histone demethylases, KDM2B (ref.(123)), KDM5B (refs.”
Targeting Cancer Cell Dormancy
Recasens, A., & Munoz, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.12.004 · Cited by 356
Targeting epigenetic regulators to overcome drug resistance in cancers
Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 311
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
“KDM2 [71], KDM3 [45], KDM5 [23,39,45,60,72], and KDM6 [45] have been found to be upregulated in different tumor models of drug tolerance and resistance to various drugs.”
Background
Metadata
- Authors
- Staberg, M., Rasmussen, R. D., Michaelsen, S. R., Pedersen, H., Jensen, K. E., Villingshøj, M., Skjoth‐Rasmussen, J., Brennum, J., Vitting‐Seerup, K., Poulsen, H. S., & Hamerlik, P.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2018-02-12
- Volume
- 12
- Issue
- 3
- Pages
- 406-420
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2794248987
- Cited by
- 77
- References
- 10
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.